BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. About Cirtec Medical Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing in active implant systems, interventional devices, ...

KORU Medical Systems (KRMD) FY Conference August 13, 2025 10:30 AM ET Speaker0Alright. Good morning, everyone, and welcome to this year's Canaccord Genuity Global Growth Conference. My name is Caitlin Cronin, and I'm on the medical device team here at Canaccord Genuity. Coru Medical is joining us today, and they're a medical device company focused on innovative portable solutions for the drug delivery market. We're very pleased to be joined today by Linda Tharby, President and CEO, as well as Tom Adams, CFO ...

KORU Medical Systems (KRMD) Q2 2025 Earnings Call August 06, 2025 04:30 PM ET Speaker0Hello and welcome to the Kuru Medical Systems Second Quarter twenty twenty five Financial Results Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to Louisa Smith of the Gilmartin Group.Please go ahead.Speaker1Thank you, Judit ...

Q2 2025 Earnings Call August 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forwa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) 100 Corporate Drive ...

EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES Q2 2025 FINANCIAL RESULTS, INCLUDING RECORD DOUBLE-DIGIT REVENUE, AND RAISES 2025 REVENUE GUIDANCE MAHWAH, NJ – August 6, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient- centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financ ...

KORU Medical Systems (KRMD) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalLinda Tharby - President, Director & CEOTom Adams - Chief Financial OfficerCaitlin Cronin - Director Conference Call Participants Frank Takkinen - Senior Research AnalystChase Knickerbocker - Senior Equity Research Analyst - HealthcareJason Bednar - Research AnalystAnderson Schock - Research Analyst Operator Greetings, and welcome to KORU Medical Systems first quarter twenty twenty five ea ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 reached $9.6 million, an 18% increase year-over-year, marking a record for the company [7][23] - Gross margin improved to 62.8%, a 50 basis point increase compared to the same period last year [9][26] - The company raised its 2025 revenue guidance to a range of $38.5 million to $39.5 million, representing a 15% to 17% year-over-year growth [9][29] Business Line Data and Key Metrics Changes - Domestic core revenues were $6.9 million, a 16% increase year-over-year, driven by new patient starts and market share gains [23] - International core business revenues reached $2.4 million, representing a 36% growth over the prior year, driven by expansion into new geographies and a key tender win [24][12] - Pharma services and clinical trials revenues declined by 39% to $300,000 due to lower clinical trial orders [24] Market Data and Key Metrics Changes - The overall SCIG market grew approximately 10% in Q1, while the company's domestic core business grew 16% [12] - Internationally, the company achieved 36% growth, driven by patient growth and new distributor relationships in the Middle East and North Africa [12] - The total international SCIG total addressable market (TAM) is estimated at $60 million, with the company currently holding approximately a 10% share [16] Company Strategy and Development Direction - The company aims to expand its platform to support subcutaneous delivery of additional large volume drugs, capitalizing on the shift from IV to subcutaneous formulations [11] - The strategic vision includes strengthening the core business while pursuing new drug opportunities, with a focus on operational efficiencies and market expansion [10][11] - The company plans to submit two additional commercialized drugs for FDA clearance by the end of 2025, bringing the total pipeline to five planned submissions [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for the core business, citing a resilient market growth even amid macroeconomic uncertainties [15] - The company is optimistic about its international expansion plans, targeting a growth in market share from 10% to 30%-40% over the next several years [16] - Management reiterated expectations for positive cash flow from operations in 2025, with a focus on improving operating leverage [30] Other Important Information - The company has nine active collaborations with pharmaceutical partners, with a robust pipeline of 17 total opportunities [17] - The company is actively monitoring the changing policy environment regarding tariffs and supply chain impacts [27] Q&A Session Summary Question: Thoughts on adding new drugs without current partnerships - Management is excited about pursuing drugs independently, driven by strong relationships with specialty pharmacies and the potential for revenue growth with minimal investment [41][43] Question: Revenue cadence throughout the year - Management expects international revenue growth to be around 30%, with some impact from distributor stocking orders in Q2 [46][48] Question: Prefilled syringe opportunity and tender details - Prefilled syringe penetration in the US is now over 65%, with plans for further penetration outside the US [50][51] Question: Update on ePump opportunity and distributor dynamics - The company sees potential for increased volumes of consumables with e pumps, driven by new market openings and share gains [60] Question: Market opportunity for new drugs - The iron chelation drug has an estimated patient base of 30,000, while the antibiotic drug has over 300,000 patients, with significant potential for home administration [88][90]

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, timing of 510(k) clearances and financial guidance for fiscal 2025. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future ...

Revenue and Profitability - The company reported net revenues of $9.6 million for Q1 2025, a 17.5% increase from $8.2 million in Q1 2024, driven by a 16.4% growth in domestic core revenues and a 35.6% increase in international core revenues [75]. - Gross profit for Q1 2025 was $6.0 million, an 18.5% increase from $5.1 million in Q1 2024, with a gross margin of 62.8%, up from 62.3% in the prior year [76][81]. - The company experienced a net loss of $1.2 million in Q1 2025, a 39.8% improvement from a net loss of $1.9 million in Q1 2024 [85]. Expenses - Operating expenses increased to $7.3 million in Q1 2025, compared to $7.1 million in Q1 2024, primarily due to a rise in selling, general, and administrative expenses [77][83]. - Selling, general, and administrative expenses rose by 11.2% to $6.0 million in Q1 2025, driven by increased compensation-related expenses and legal fees [83]. - Research and development expenses decreased by 24.5% to $1.1 million in Q1 2025, primarily due to timing of project spending [84]. Cash Flow and Investments - Cash on hand as of March 31, 2025, was $8.7 million, with inventory increasing to $3.3 million, reflecting a $0.5 million rise from December 31, 2024 [86][87]. - Net cash used in operating activities was $0.2 million for Q1 2025, an improvement from $0.3 million in Q1 2024, primarily due to a lower net loss and changes in working capital [90][91]. - The company invested $0.4 million in capital expenditures for manufacturing equipment related to new consumables production lines in Q1 2025 [92]. - The company anticipates that cash on hand and cash flows from operations will be sufficient to meet requirements for at least the next twelve months [88]. Accounting and Market Risk - No significant accounting policies have been adopted that would impact the financial statements [94]. - There are no applicable quantitative and qualitative disclosures about market risk [95].